Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in Pemphigus Vulgaris
NCT00135720Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2004
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pemphigus vulgaris (PV) comparing Etanercept with Placebo (2 arms). Primary endpoints: Mean time to reduce active lesions by 50% and Determine whether etanercept is a possible steroid-sparing treatment option. Started Jun 2004; status: completed.
02
Drugs
etanercept
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT00135720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135720.